Almirall, LLC

FDA approves Eli Lilly's Ebglyss (lebrikizumab) for moderate-to-severe atopic dermatitis, offering once-monthly dosing. Ebglyss targets IL-13, providing clear skin in 38% of patients at 16 weeks, compared to 12% with placebo. Common side effects include eye inflammation, injection site reactions, and shingles.

Eli Lilly's Ebglyss (lebrikizumab-lbkz) receives FDA approval for treating moderate-to-severe atopic dermatitis in individuals aged 12+ weighing at least 40kg, not well controlled by topical therapies. Ebglyss, a targeted IL-13 inhibitor, offers a monthly maintenance injection with initial dosing and potential itch relief, based on ADvocate 1, 2, and ADhere studies. Common side effects include eye and eyelid inflammation, injection site reactions, and shingles. Lilly plans to commercialize Ebglyss in the US and offers support services for patient access.

Eli Lilly's EBGLYSS (lebrikizumab-lbkz) receives FDA approval for treating moderate-to-severe atopic dermatitis in adults and children aged 12+. The IL-13 inhibitor, designed for those unresponsive to topical treatments, can be used with or without corticosteroids. It starts with a 500mg dose at weeks 0 and 2, followed by 250mg every two weeks until week 16, then shifts to a monthly maintenance dose. Clinical trials ADvocate 1, 2, and ADhere supported the approval. Lilly plans to launch EBGLYSS in the US and offers patient support programs, including co-pay assistance. The treatment is also approved in the EU and Japan, with further market expansion planned for late 2024.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.